Collaboration with Europe’s leading cancer hospital - largest clinical trial on 3D printed medicine
25 July 2024
Researchers from Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø School of Pharmacy have published their recent collaboration with FABRX, a Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø School of Pharmacy spinout, and Gustave Roussy, Europe’s leading cancer research hospital, for the development of multi-active medicines produced via 3D printing
Anna Kirstine Jø°ù²µ±ðnsen, PhD student in the Centre for Doctoral Training (CDT) for Transformative Pharmaceutical Technologies, and ProfessorÌýAbdul Basit from Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø School of Pharmacy have published their recent collaboration with FABRX and Gustave Roussy Cancer Campus on the development of personalised breast cancer medicines with multiple actives through a pharmaceutical 3D printer. The medicines are included in the largest clinical trial on medicines produced via 3D printing to date where they will treat 200 breast cancer patients to help improve adherence to tamoxifen.
Ìý
To read the publication, please visit:
Collaborators’ websites: &
For any queries or more information, please contact Prof Abdul Basit (a.basit@ucl.ac.uk) Ìý |